EP1206252A4 - Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von polymeren - Google Patents

Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von polymeren

Info

Publication number
EP1206252A4
EP1206252A4 EP00920286A EP00920286A EP1206252A4 EP 1206252 A4 EP1206252 A4 EP 1206252A4 EP 00920286 A EP00920286 A EP 00920286A EP 00920286 A EP00920286 A EP 00920286A EP 1206252 A4 EP1206252 A4 EP 1206252A4
Authority
EP
European Patent Office
Prior art keywords
folate
amplification
polymers
tumor cells
mediated targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00920286A
Other languages
English (en)
French (fr)
Other versions
EP1206252A1 (de
Inventor
Gregory John Russell-Jones
John Fergus Mcewan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Access Pharmaceuticals Australia Pty Ltd
Original Assignee
Access Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access Pharmaceuticals Australia Pty Ltd filed Critical Access Pharmaceuticals Australia Pty Ltd
Publication of EP1206252A1 publication Critical patent/EP1206252A1/de
Publication of EP1206252A4 publication Critical patent/EP1206252A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/20—Post-etherification treatments of chemical or physical type, e.g. mixed etherification in two steps, including purification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C08F251/02—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof on to cellulose or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00920286A 1999-05-04 2000-05-04 Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von polymeren Withdrawn EP1206252A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ014799 1999-05-04
AUPQ0147A AUPQ014799A0 (en) 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
PCT/AU2000/000406 WO2000066091A1 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers

Publications (2)

Publication Number Publication Date
EP1206252A1 EP1206252A1 (de) 2002-05-22
EP1206252A4 true EP1206252A4 (de) 2005-02-16

Family

ID=3814354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00920286A Withdrawn EP1206252A4 (de) 1999-05-04 2000-05-04 Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von polymeren

Country Status (5)

Country Link
EP (1) EP1206252A4 (de)
JP (1) JP2002543111A (de)
AU (2) AUPQ014799A0 (de)
CA (1) CA2372841A1 (de)
WO (1) WO2000066091A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112608398A (zh) * 2020-11-30 2021-04-06 西安交通大学 一种共载阿霉素和铂类药物的还原/pH敏感型多糖基纳米前药及其制备方法和应用

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
EP1434603B1 (de) * 2001-09-28 2009-12-16 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
ES2324708T3 (es) * 2002-05-15 2009-08-13 Endocyte, Inc. Conjugados de vitamina-mitomicina.
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US7601332B2 (en) * 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1789391B1 (de) 2004-07-23 2017-06-28 Endocyte, Inc. Zweiwertige linker und konjugate davon
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1863816B1 (de) 2005-03-16 2014-06-25 Endocyte, Inc. Synthese und aufreinigung von pteroinsäure und konjugaten davon
EP1948241B1 (de) 2005-08-19 2014-03-05 Endocyte, Inc. Multi-arzneimittel-liganden-konjugate
EP1928503B1 (de) 2005-08-24 2012-10-03 ImmunoGen, Inc. Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
WO2007080114A2 (en) * 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
AR061181A1 (es) 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) * 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
JP2010528115A (ja) 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー エポチロン化合物およびアナログの製造方法
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2009133545A2 (en) * 2008-04-30 2009-11-05 Ben Gurion University Of The Negev Research And Development Authority Vascular delivery systems
US8546425B2 (en) 2008-09-17 2013-10-01 Purdue Research Foundation Folate receptor binding conjugates of antifolates
AU2009302387B2 (en) 2008-10-07 2014-12-04 Rexahn Pharmaceuticals, Inc HPMA - docetaxel or gemcitabine conjugates and uses therefore
EP2210616A1 (de) * 2009-01-21 2010-07-28 Centre National de la Recherche Scientifique Multifunktionelle Stealth-Nanoteilchen zur Verwendung in der Biomedizin
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
CN104587484A (zh) 2009-10-13 2015-05-06 瑞沙恩医药公司 用于抗癌剂递送的聚合物系统
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR20220123130A (ko) * 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
SG11201502896XA (en) 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
EA201890915A1 (ru) 2012-11-15 2018-09-28 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
DE202014011600U1 (de) 2013-10-18 2023-05-31 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
WO2015073678A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
CN106619571B (zh) * 2017-01-03 2020-04-07 西南交通大学 一种提高细胞内吞和细胞核靶向的聚合物纳米载体及其制备方法
EP3571230A4 (de) 2017-01-20 2020-12-16 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd137+-zellen
CN112135838A (zh) * 2018-03-29 2020-12-25 日油株式会社 分解性聚乙二醇键合物
CN112533640A (zh) * 2018-05-04 2021-03-19 双亥生命科学株式会社 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466038A1 (de) * 1990-07-12 1992-01-15 E.R. SQUIBB & SONS, INC. Wasser-dispergierbare antifungizide Polyenkomplexen
WO1994027641A1 (en) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification of the vitamin b12 uptake system using polymers
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO2000035422A2 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466038A1 (de) * 1990-07-12 1992-01-15 E.R. SQUIBB & SONS, INC. Wasser-dispergierbare antifungizide Polyenkomplexen
WO1994027641A1 (en) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification of the vitamin b12 uptake system using polymers
WO1998016202A2 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Fusogenic liposome composition and method
WO2000035422A2 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BENNS, J.M.; KIM, S.W.: "Tailoring new gene delivery designs for specific targets", JOURNAL OF DRUG TARGETING, vol. 8, no. 1, 2000, SWITZERLAND, pages 1 - 12, XP002968594 *
FLANAGAN P A: "EVALUATION OF PROTEIN-N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER CONJUGATES AS TARGETABLE DRUG-CARRIERS. \2.BODY DISTRIBUTION OF CONJUGATES CONTAINING TRANSFERRIN, ANTITRANSFERRIN RECEPTOR ANTIBODY OR ANTI-THY 1.2 ANTIBODY AND EFFECTIVENESS OF TRANSFERRIN-CONTAINING DAUNOMYCIN CONJUGATES AGAINST MO", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 18, no. 1, January 1992 (1992-01-01), pages 25 - 37, XP000238213, ISSN: 0168-3659 *
PUTNAM D ET AL: "Polymer conjugates with anticancer activity", ADVANCES IN POLYMER SCIENCE; BIOPOLYMERS II SPRINGER-VERLAG, HEIDELBERGER PLATZ 3, D-1000 BERLIN, GERMANY; SPRINGER-VERLAG NEW YORK, INC., 175 FIFTH AVENUE, NEW YORK, NEW YORK 10010, USA SERIES : ADVANCES IN POLYMER SCIENCE (ISSN 0065-3195), 1995, pages 55 - 123, XP009041750, ISSN: 3-540-58788-8 0-387-58788-8 *
REDDY J A ET AL: "FOLATE-MEDIATED TARGETING OF THERAPEUTIC AND IMAGING AGENTS TO CANCERS", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, XX, XX, vol. 15, no. 6, 1998, pages 587 - 627, XP000901554, ISSN: 0743-4863 *
See also references of WO0066091A1 *
STELLA B ET AL: "PEG-COATED BIODEGRADABLE POLYCYANOACRYLATE NANOPARTICLES COUPLED TO FOLIC ACID FOR TUMORAL INTRACELLULAR TARGETING", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, XX, XX, no. 26, 1999, pages 799 - 800, XP001181024, ISSN: 1022-0178 *
UMEMOTO N ET AL: "MOLECULAR DESIGN OF METHOTREXATE-ANTIBODY CONJUGATES FOR TARGETED CANCER TREATMENT", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, LANCASTER, PA, US, vol. 7, no. 2, April 1992 (1992-04-01), pages 191 - 219, XP009020458 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112608398A (zh) * 2020-11-30 2021-04-06 西安交通大学 一种共载阿霉素和铂类药物的还原/pH敏感型多糖基纳米前药及其制备方法和应用

Also Published As

Publication number Publication date
WO2000066091A1 (en) 2000-11-09
AUPQ014799A0 (en) 1999-05-27
CA2372841A1 (en) 2000-11-09
EP1206252A1 (de) 2002-05-22
AU4094300A (en) 2000-11-17
JP2002543111A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
EP1206252A4 (de) Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von polymeren
EP1206251A4 (de) Verstärkung der folate-vermittelten zielgerichtetheit auf tumorzellen unter verwendung von nanopartikeln
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
DE60130723D1 (de) Implantierbarer Herzschrittmacher zur Optimierung der Reizungseffektivität
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
GB9930691D0 (en) Improvements relating to double-stranded RNA inhibition
HK1048820A1 (zh) 用於雙導向病毒感染和導向癌細胞的組合物和方法
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
HUP0500180A2 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
AU6208100A (en) Cancer treatment using angiopoietins targeted to aminophospholipids
AU2002235168A1 (en) Targeting pluripotent stem cells to tissues
AU3881100A (en) Human tumor necrosis factor receptor-like genes
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
AU2135001A (en) Targeting of endosomal growth factor processing as anti-cancer therapy
AU2001272967A1 (en) Imaging and targeting tumors using sickle cells
EP1218393A4 (de) Zellgerichtete zusammensetzungen und methoden zu deren verwendung
GB0011060D0 (en) Improvements relating to gene directed enzyme prodrug therapy
AU2409602A (en) Method of testing anticancer agent-sensitivity of tumor cells
AU4774200A (en) Long term cell culture of human carcinoma
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
IL147097A0 (en) Methods of imaging and targeting tumor vasculature
GB2353306B (en) Improvements to ploughs
EP1204673A4 (de) Zusammensetzungen und verfahren zur erhöhung der sensibilität von krebszellen gegenüber mitotischem stress
IL149621A0 (en) Selectable cell surface marker genes
GB2353304B (en) Improvements to ploughs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020215

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20050103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201